BPC-157 vs GHK-Cu: Tissue Repair Showdown

## Introduction Among research peptides studied in tissue repair biology, two names appear again and again: BPC-157 and GHK-Cu. Both are extensively published in preclinical literature, both are associated with connective tissue and fibroblast research, and both are frequently stocked side by side in research supply catalogs — which is exactly why the comparison gets asked so often. But structurally and mechanistically, they are very different compounds. BPC-157 is a 15-amino-acid synthetic peptide derived from a gastric protection sequence, studied primarily in tendon, gut, and systemic wound models. GHK-Cu is a naturally occurring copper-binding tripeptide found in human plasma, studied most heavily in skin, collagen, and gene-expression remodeling research. This guide compares them head to head: structure, mechanism, the published preclinical record, and which research domains each is most commonly associated with. All discussion is framed around laboratory research; neither compound is approved for human or veterinary use. ## BPC-157 Overview BPC-157 is a synthetic pentadecapeptide — a chain of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is a partial sequence of the body protection compound (BPC), a protein fraction originally isolated from human gastric juice. Its molecular weight is approximately 1419 Da. The compound's research literature is unusually broad. Published studies span tendon and ligament models, gastrointestinal injury, blood vessel formation, oxidative stress protection, and even central nervous system endpoints. The central theme is cytoprotection — BPC-157 is studied for its ability to protect cells and support tissue integrity across many tissue types, a property the Sikiric group has documented across hundreds of publications since the 1990s. ### Key Published Findings The mechanistic work on BPC-157 centers on fibroblast biology and signaling. Chang and colleagues (2011) demonstrated that BPC-157 accelerated the outgrowth of tendon fibroblasts from explants, increased cell survival under oxidative stress, and promoted fibroblast migration in a dose-dependent manner — effects linked to activation of the FAK-paxillin signaling pathway, a well-known regulator of cell motility. > **Citation:** Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." *Journal of Applied Physiology*. 2011;110(3):774-780. [PubMed PMID: 21030672](https://pubmed.ncbi.nlm.nih.gov/21030672/) Earlier, Staresinic and colleagues (2003) reported that BPC-157 accelerated the healing of transected rat Achilles tendon, a finding that anchors much of the compound's soft-tissue research reputation. > **Citation:** Staresinic M, Sebecic B, Patrlj L, et al. "Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon." *Journal of Orthopaedic Research*. 2003;21(6):976-983. [PubMed PMID: 14554208](https://pubmed.ncbi.nlm.nih.gov/14554208/) For a deeper dive, see our [What Is BPC-157? Complete Research Guide](/insights/what-is-bpc-157). ## GHK-Cu Overview GHK-Cu is the copper(II) complex of glycyl-L-histidyl-L-lysine, a tripeptide of just three amino acids. Unlike BPC-157, it is endogenous — GHK was first isolated from human plasma in 1973, and its plasma concentration declines markedly with age (from roughly 200 ng/mL at age 20 to about 80 ng/mL by age 60). Its molecular weight is approximately 340 Da as the free peptide. GHK binds copper(II) with high affinity, and the GHK-Cu complex is the biologically active form studied in most of the literature. Pickart's 2018 review synthesized decades of research: GHK-Cu stimulates collagen, elastin, and glycosaminoglycan synthesis, supports dermal fibroblast function, promotes blood vessel and nerve outgrowth, and — per newer gene-expression profiling data — modulates the expression of numerous genes involved in tissue remodeling, antioxidant defense, and inflammatory signaling. > **Citation:** Pickart L, Margolina A. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." *International Journal of Molecular Sciences*. 2018;19(7):1987. [PubMed PMID: 29986520](https://pubmed.ncbi.nlm.nih.gov/29986520/) The connective-tissue evidence goes back further. Maquart and colleagues (1993) demonstrated in rat experimental wounds that the GHK-Cu complex stimulated the accumulation of collagen and other connective tissue components in vivo, establishing the compound's matrix-remodeling credentials early. > **Citation:** Maquart FX, Bellon G, Chaqour B, et al. "In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds." *Journal of Clinical Investigation*. 1993;92(5):2368-2376. [PubMed PMID: 8227353](https://pubmed.ncbi.nlm.nih.gov/8227353/) ## Head-to-Head Comparison | Feature | BPC-157 | GHK-Cu | |---|---|---| | **Structure** | 15-amino-acid synthetic peptide (1419 Da) | 3-amino-acid copper complex (340 Da) | | **Origin** | Synthetic; derived from gastric juice protein fraction | Endogenous; found in human plasma, saliva, urine | | **Copper binding** | No | Yes — the Cu(II) complex is the active form | | **Primary research focus** | Tendon/ligament, GI tract, systemic wound models | Skin, collagen synthesis, gene-expression remodeling | | **Key signaling** | FAK-paxillin pathway, VEGF, nitric oxide modulation | Collagen/elastin synthesis, metalloproteinase regulation, gene modulation | | **Fibroblast effects** | Outgrowth, migration, survival under stress | Collagen production, growth factor expression | | **Angiogenesis** | Studied (VEGFR2 activation reported) | Studied (vessel outgrowth reported) | | **Gene expression data** | Limited | Extensive (multiple profiling studies) | | **Oral stability** | Stable in gastric fluid (widely reported) | Degraded in GI tract (topical/injectable research routes) | | **Research history** | 1990s–present (Sikiric group et al.) | 1970s–present (Pickart et al.) | ## Key Differences **Size and complexity.** BPC-157 is five times larger than GHK and carries a more complex pharmacology across tissue types. GHK-Cu's small size and endogenous origin make it one of the most-studied signaling peptides in skin biology. **Endogenous vs synthetic.** GHK exists naturally in the body and declines with age — much of its research framing concerns restoring a declining signal. BPC-157 is a synthetic fragment inspired by a gastric protein; it has no known endogenous circulating form at research-relevant levels. **Research center of gravity.** BPC-157's deepest literature is in musculoskeletal and gastrointestinal models — tendon transection, ligament injury, ulcer and fistula studies. GHK-Cu's deepest literature is in dermal and matrix biology — collagen synthesis, wound chambers, skin remodeling, and large-scale gene-expression profiling. **Mechanistic clarity.** GHK-Cu has the better-characterized molecular story: copper delivery, collagen gene upregulation, and documented shifts across hundreds of genes. BPC-157's mechanism remains more phenomenological — the FAK-paxillin and VEGF findings are solid, but the compound's famously broad effects across tissues still lack a single unifying receptor-level explanation in the published record. ## Which Is Studied for What In practice, laboratories tend to reach for each compound in different experimental contexts: - **Tendon and ligament models:** BPC-157 dominates this literature (Achilles transection, tendon fibroblast outgrowth). - **Gastrointestinal research:** BPC-157 — its gastric origin and oral stability make it the default in gut-barrier and ulcer models. - **Skin and collagen research:** GHK-Cu — the collagen synthesis and dermal fibroblast data are the most extensive of any peptide in this niche. - **Gene-expression remodeling:** GHK-Cu — the Pickart 2018 review and related profiling work are frequently cited in aging-biology contexts. - **Multi-tissue cytoprotection screening:** BPC-157 — studied across liver, brain, and systemic injury models where GHK-Cu has little published presence. - **Combination research:** The two are sometimes studied together (alongside TB-500) in multi-pathway tissue repair designs, since their mechanisms do not obviously overlap. ## Frequently Asked Questions ### Are BPC-157 and GHK-Cu the same type of compound? No. BPC-157 is a 15-amino-acid synthetic peptide derived from a gastric protein sequence. GHK-Cu is a naturally occurring copper-binding tripeptide found in human plasma. They differ in size, origin, and mechanism. ### Which has more published research? Both are extensively published, but in different domains. BPC-157's literature is broader across tissue types (tendon, gut, liver, CNS). GHK-Cu's literature is deeper in skin/matrix biology and gene-expression profiling, with a research history stretching back to the 1970s. ### Do BPC-157 and GHK-Cu work through the same pathway? No. BPC-157's reported effects involve FAK-paxillin signaling, VEGF, and nitric oxide modulation. GHK-Cu acts through copper delivery, collagen gene upregulation, and broad gene-expression shifts. Their mechanisms are distinct and potentially complementary in combination research designs. ### Is GHK-Cu naturally found in the body? Yes. GHK was first isolated from human plasma in 1973. Circulating levels decline with age, which is part of the rationale for its study in aging-related tissue research. ### What purity should research-grade material be? Reputable suppliers provide both compounds at ≥99% purity verified by HPLC with mass spectrometry identity confirmation, accompanied by a batch-specific Certificate of Analysis. [Browse the COA library](/coas) for examples. ## Conclusion BPC-157 and GHK-Cu earn their frequent pairing honestly: both are among the most-published peptides in tissue repair research, and both act on fibroblasts and connective tissue. But the comparison reveals two fundamentally different research tools — a broad-spectrum synthetic cytoprotective peptide with deep musculoskeletal and GI literature, and a small endogenous copper complex with unmatched depth in skin, collagen, and gene-remodeling research. For laboratories, the choice is rarely either/or. The published record supports each in its own domain, and their non-overlapping mechanisms are precisely why combination studies exist. The honest summary of the literature: BPC-157 for breadth, GHK-Cu for dermal depth. --- **Internal link suggestions:** - Product: [BPC-157 10MG](/product/bpc-157-10mg) - Product: [GHK-Cu 50MG](/product/ghk-cu-50mg) - Related guide: [What Is BPC-157?](/insights/what-is-bpc-157) For laboratory research use only. Not for human or veterinary use.